Antibody Production Deficiency With Normal IgG Levels in Bronchiectasis of Unknown Etiology

Vendrell, Montserrat; Gracia, Javier de; Rodrigo, María-José; Cruz, María Jesús; Álvarez, Antonio; García, M.; Miravitlles, Marc

doi:10.1378/chest.127.1.197

Cited by 55 publications

(34 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The nonresponders had a significantly higher incidence of otitis media, lower serum IgG2-subclass levels and lower pre-immunisation antibody titres to S. pneumoniae and Hib, and had recurrent pneumonia more frequently (in this latter case, differences were not significant due to the low number of nonresponders) [8], similar to the first case described by AMBROSINO et al [9].…”

Section: Antibody Deficiency In Bronchiectasissupporting

confidence: 77%

“…We totally agree that a sizeable fraction of patients with bronchiectasis of unknown cause can now be classified as bronchiectasis associated with polysaccharide antibodyresponse deficiency [1,8,10,11]. However, before this diagnosis can be established and substitution therapy with immunoglobulins can be indicated, comprehensive immunological evaluation is mandatory.…”

Section: Antibody Deficiency In Bronchiectasismentioning

confidence: 68%

See 1 more Smart Citation

Antibody deficiency in bronchiectasis

Miravitlles¹

2005

European Respiratory Journal

View full text Add to dashboard Cite

Section: Antibody Deficiency In Bronchiectasissupporting

confidence: 77%

Section: Antibody Deficiency In Bronchiectasismentioning

confidence: 68%

Antibody deficiency in bronchiectasis

Miravitlles¹

2005

European Respiratory Journal

View full text Add to dashboard Cite

“…Antibody deficiency with normal IgG subclasses has been reported and could lead to severe infections and bronchiectasis [23]. It is important to get appropriate antibody response to proper vaccination to document the functional capacity of a patient’s humoral immunity [5, 10].…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Intravenous Gammaglobulin for Immunoglobulin G Subclass and/or Antibody Deficiency in Adults

Abdou¹,

Greenwell

Mehta³

et al. 2009

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Background: The clinical significance and efficacy of treating patients who have immunoglobulin (Ig) G subclass deficiency and/or antibody deficiency with Ig-replacement therapy has been debated. There are no clear guidelines to recommend intravenous gammaglobulin (IgIV) in these patients as there are few published studies documenting its efficacy. Methods: We studied in an open-label protocol 10 adult patients with recurrent respiratory infections and IgG subclass and/or antibody deficiency. All patients received monthly IgIV for 12 months and then were observed for 3 months without IgIV infusions. We studied quality of life, incidence of infections, need for antibiotics, frequency of hospitalizations due to infections, IgG subclass and antibody (tetanus and pneumococcal) levels. Innate immunity was evaluated by studying the status of Toll-like receptors and polymorphisms, mannan-binding lectin levels and genotypes. Correction of the immune defects during IgIV therapy was evaluated. Results: Monthly IgIV significantly improved quality of life, decreased the number of infections and the need for antibiotics, and improved IgG subclass and antibody serum levels. No consistent finding of innate immunity could be detected. Conclusions: IgIV could be beneficial in patients with IgG subclass or antibody deficiency.

show abstract

“…However, the study was small, with no matched controls in which the immunological criteria used for SAD were queried [81]. Other larger series of adult patients with bronchiectasis show that the incidence of specific antibody deficiency varies from 4% to 11% [65,82]. Antibody responses to polysaccharide vaccines are variable and depend on age.…”

Section: Bronchiectasismentioning

confidence: 99%

Infectious and Noninfectious Pulmonary Complications in Patients With Primary Immunodeficiency Disorders

Yazdani

Abolhassani

et al. 2017

J Investig Allergol Clin Immunol

View full text Add to dashboard Cite

Primary immunodeficiency disorders (PIDs) are caused by 1 or more defects of the immune system. Patients are more likely to experience recurrent and/or severe infections and tend to develop a wide range of complications. Respiratory diseases are the main and initial manifestation in most cases and the most common complication. Pulmonary complications cause significant morbidity and mortality in patients with PIDs. Early diagnosis and appropriate treatment can prevent or at least slow the development of respiratory complications. Since the spectrum of pulmonary complications in PIDs is broad, we divided pulmonary complications into upper respiratory complications (eg, sinusitis, otitis media, and laryngeal angioedema) and lower respiratory complications (eg, pneumonia, bronchitis, bronchiectasis, interstitial lung diseases, organizing pneumonia, pulmonary adenopathies and malignancies, hyperreactive airway diseases, pulmonary dysgenesis, and adverse reactions to treatment). This review covers the main respiratory manifestations in patients with PIDs. Key words: Primary immunodeficiency disorders. Pulmonary complications. Upper respiratory tract. Lower respiratory tract. ResumenLas inmunodeficiencias primarias (PIDs) son enfermedades causadas por uno o más defectos del sistema inmunológico. Estos pacientes presentan con frecuencia infecciones recidivantes y/o severas así como otro tipo de complicaciones. Las patologías respiratorias son la principal y más frecuente manifestación y complicación de las PIDs. Las complicaciones de estas patologías pulmonares constituyen una de las principales causas de morbimortalidad entre los pacientes que sufren PIDs. El diagnóstico temprano y el tratamiento adecuado pueden prevenir, o al menos retrasar, la aparición de las complicaciones respiratorias en estos pacientes. Dado que el espectro de las enfermedades pulmonares es muy amplio, hemos dividido estas complicaciones entre aquellas que afectan a las vías aéreas superiores (sinusitis, otitis media y angioedema laríngeo, etc.) y las que afectan a las vías aéreas bajas (neumonía, bronquitis, bronquiectasias, enfermedades pulmonares intersticiales, neumonía organizada, adenopatías pulmonares y neoplasias, hiperreactividad bronquial, disgenesia pulmonar y las debidas a los efectos secundarios del tratamiento instaurado). Este artículo revisa las manifestaciones respiratorias que se observan más frecuentemente en los pacientes con PIDs. Palabras clave: Inmunodeficiencias primarias. Complicaciones pulmonares. Vías respiratorias altas. Vías respiratorias bajas.

show abstract

Antibody Production Deficiency With Normal IgG Levels in Bronchiectasis of Unknown Etiology

Cited by 55 publications

References 25 publications

Antibody deficiency in bronchiectasis

Antibody deficiency in bronchiectasis

Efficacy of Intravenous Gammaglobulin for Immunoglobulin G Subclass and/or Antibody Deficiency in Adults

Infectious and Noninfectious Pulmonary Complications in Patients With Primary Immunodeficiency Disorders

Contact Info

Product

Resources

About